Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • 757 Phase 1/2a clinical trial...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab

Bibliographic Details
Published in:Journal for ImmunoTherapy of Cancer
Main Authors: Michael Chisamore, Jeffrey Yachnin, Ana Carneiro, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Petra Holmkvist, Andres McAllister, Marie Borggren, Ingrid Karlsson, Mark Cragg, Lars Ny, Zsuzsanna Pápai, Kristoffer Staahl Rohrberg, Kirstie Cleary, Jan Anders Nilsson, Sean Lim, Johan E Wallin, Istvan Lang, Harriet Walter, Rikke H Lovendahl Eefsen, Edvard Abel, Robert Oldham, Susanne Gertsson
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • 1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
    by: Monika Semmrich, et al.
    Published: (2023-11-01)
  • 725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
    by: Monika Semmrich, et al.
    Published: (2020-11-01)
  • CHIMIA 2021, 75, 757
    by: Werner Bonrath, et al.
    Published: (2022-10-01)
  • Fn14 and TNFR2 as regulators of cytotoxic TNFR1 signaling
    by: Daniela Siegmund, et al.
    Published: (2023-11-01)
  • Co-modulation of TNFR1 and TNFR2 in an animal model of multiple sclerosis
    by: Timon Fiedler, et al.
    Published: (2023-04-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs